keyword
MENU ▼
Read by QxMD icon Read
search

Durvalumab

keyword
https://www.readbyqxmd.com/read/29662547/pd-l1-expression-testing-in-non-small-cell-lung-cancer
#1
REVIEW
Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemí Reguart
In recent years, immunotherapy has revolutionized and changed the standard of care in patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death ligand-1 (PD-L1) have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy. Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as nivolumab, atezolizumab and pembrolizumab in first-line (only the latter) and second-line settings, and more recently, durvalumab as maintenance after chemoradiotherapy in locally advanced disease...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29644490/emerging-role-of-immunotherapy-in-advanced-urothelial-carcinoma
#2
REVIEW
Vadim S Koshkin, Petros Grivas
PURPOSE OF REVIEW: Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors that are changing this treatment landscape. RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29623110/clinical-assessment-of-immune-related-adverse-events
#3
REVIEW
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across diverse trials. Adverse events of an immune nature associated with these agents frequently affect the skin, colon, endocrine glands, lungs and liver...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29606979/pd-1-and-pd-l1-inhibitors-after-platinum-based-chemotherapy-or-in-first-line-therapy-in-cisplatin-ineligible-patients-dramatic-improvement-of-prognosis-and-overall-survival-after-decades-of-hopelessness-in-patients-with-metastatic-urothelial-cancer
#4
REVIEW
Irene Resch, Shahrokh F Shariat, Kilian M Gust
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained disease control...
2018: Memo
https://www.readbyqxmd.com/read/29594250/anti-pd-l1-durvalumab-combined-with-cetuximab-and-radiotherapy-in-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-a-phase-i-ii-study-ducro
#5
Pierluigi Bonomo, Isacco Desideri, Mauro Loi, Monica Mangoni, Mariangela Sottili, Livia Marrazzo, Cinzia Talamonti, Daniela Greto, Stefania Pallotta, Lorenzo Livi
Introduction and background: Head and neck squamous cell carcinoma (HNSCC) has been increasingly recognized as an immune suppressive malignancy. The efficacy of immune checkpoint inhibitors (ICI's) in the context of recurrent/metastatic (R/M) setting anticipates the possible integration of immunotherapy into the therapeutic armamentarium of locally advanced disease. Durvalumab (DUR) is a humanized monoclonal IgG1, anti-PD-L1 antibody with promising data in R/M HNSCC. The aim of our study is to test the antitumor activity of a combined regimen incorporating an immune checkpoint inhibitor into a conventional bio-radiation strategy for the cure of unfavorable locally advanced HNSCC...
February 2018: Clinical and translational radiation oncology
https://www.readbyqxmd.com/read/29593890/neoadjuvant-and-consolidation-immuno-oncology-therapy-in-stage-iii-non-small-cell-lung-cancer
#6
REVIEW
Justin Yeh, Kristen A Marrone, Patrick M Forde
Lung cancer continues to be the leading cause of cancer death worldwide. Recently, immunotherapy for non-small cell lung cancer (NSCLC) has emerged as a powerful treatment option for advanced lung cancer. The relative success of programmed death 1 (PD-1) and/or programmed death ligand 1 (PD-L1) antibodies in metastatic disease have increased interest in expanding their use to earlier stage NSCLC. The complex and diverse nature of stage III disease also invites the incorporation of immunotherapy into treatment plans in both the neoadjuvant and consolidation settings...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29572230/durvalumab-may-be-effective-in-patients-with-egfr-alk-nsclc
#7
(no author information available yet)
PD-L1 blockade with durvalumab achieves responses in patients with EGFR+ /ALK+ and EGFR- /ALK- NSCLC.
March 23, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29571563/-pd-l1-testing-in-non-small-cell-lung-carcinoma-guidelines-from-the-pattern-group-of-thoracic-pathologists
#8
Sylvie Lantuejoul, Julien Adam, Nicolas Girard, Mickael Duruisseaux, Audrey Mansuet-Lupo, Aurélie Cazes, Isabelle Rouquette, Laure Gibault, Stéphane Garcia, Martine Antoine, Jean Michael Vignaud, Françoise Galateau-Sallé, Christine Sagan, Cécile Badoual, Frédérique Penault-Llorca, Diane Damotte
Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO® , Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA® , Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ® , Genentech), durvalumab (IMFINZI® , Astra-Zeneca), and avelumab (BAVENCIO® , EMD Serono). The prescription of pembrolizumab for advanced stages non-small cell lung carcinoma (NSCLC) patients requires the demonstration of PD-L1 expression by tumor cells by immunohistochemistry (IHC) (minimum of 50% of positive tumor cells is required for first-line setting, and of 1% for second-line and beyond) and PD-L1 assay is now considered as a companion diagnostic tool for this drug...
March 20, 2018: Annales de Pathologie
https://www.readbyqxmd.com/read/29545095/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung-cancer-atlantic-an-open-label-single-arm-phase-2-study
#9
Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid, Paolo Bidoli, Paul Wheatley-Price, Keunchil Park, Ross A Soo, Yifan Huang, Catherine Wadsworth, Phillip A Dennis, Naiyer A Rizvi
BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1...
March 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29526343/-non-small-lung-cancer-ecco-esmo-congres-2017
#10
REVIEW
N Naqos, R Belbaraka, A El Omrani, M Khouchani
During the esmo congress that took place from 08 to 12 September 2017 in Madrid, non-small cell lung cancer (NSCLC) was the subject of various communications and posters. We selected the most innovative and most likely to change our daily practice These updates presented concerned both localized and metastatic lung cancers. For completely resected localized stages minimal monitoring by annual CT scan is recommended, in stage III after radio chemotherapy durvalumab treatment provides better progression-free survival (PFS)...
March 8, 2018: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/29517083/durvalumab-for-the-treatment-of-urothelial-carcinoma
#11
M Alsharedi, R Srivastava, N Elmsherghi
Immunotherapy has revolutionized cancer care in the modern era of oncology. Research in immunotherapy has led to important advances in the treatment of melanoma, non-small cell lung cancer and other malignancies using checkpoint inhibition. Multiple systemic immunotherapies have been approved or are currently being investigated for the management of urothelial malignancies (1). Five antibodies targeting the programmed cell death protein 1--programmed cell death 1 ligand 1 (PD-1--PD-L1) pathway have been approved by the U...
December 2017: Drugs of Today
https://www.readbyqxmd.com/read/29510739/measuring-multiple-parameters-of-cd8-tumor-infiltrating-lymphocytes-in-human-cancers-by-image-analysis
#12
Keith E Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha, Tobias Wiestler
BACKGROUND: Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with prognostic, pharmacodynamic, and predictive potential. We describe the development, validation, and application of advanced image analysis methods to characterize multiple immunohistochemistry-derived CD8 parameters in clinical and nonclinical tumor tissues. METHODS: Commercial resection tumors from nine cancer types, and paired screening/on-drug biopsies of non-small-cell lung carcinoma (NSCLC) patients enrolled in a phase 1/2 clinical trial investigating the PD-L1 antibody therapy durvalumab (NCT01693562), were immunostained for CD8...
March 6, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29490170/durvalumab-in-stage-iii-non-small-cell-lung-cancer
#13
LETTER
Scott J Antonia, Mustafa Özgüroğlu
No abstract text is available yet for this article.
March 1, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29486607/durvalumab-in-urothelial-cancers
#14
Pernelle Lavaud, Zineb Hamilou, Yohann Loriot, Christophe Massard
Urothelial bladder cancer is one of the most predominant malignancies worldwide with a poor prognosis when presented at an advanced or metastatic stage. Improving the therapeutic landscape in this setting has been an unmet medical need. Palliative cisplatin-based chemotherapy is currently the standard of care in first line therapies, but many patients are ineligible and few alternative therapies exist. Moreover second-line chemotherapy has minimal activity. Recently, immune-checkpoint inhibitors have shifted the therapeutic armamentarium of bladder cancer and it is now necessary to redesign the therapeutic paradigm...
February 28, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29432222/immunotherapy-for-recurrent-metastatic-head-and-neck-cancer
#15
Salvatore Alfieri, Stefano Cavalieri, Lisa Licitra
PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e...
April 2018: Current Opinion in Otolaryngology & Head and Neck Surgery
https://www.readbyqxmd.com/read/29416316/durvalumab-an-investigational-anti-pd-l1-monoclonal-antibody-for-the-treatment-of-urothelial-carcinoma
#16
REVIEW
Izak Faiena, Amy L Cummings, Anna M Crosetti, Allan J Pantuck, Karim Chamie, Alexandra Drakaki
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by programmed cell death-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1). Many antibody constructs have been developed to block these interactions and are used in clinical trials. The Food and Drug Administration has already approved a number of checkpoint inhibitors such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies including ipilimumab; anti-PD-1 monoclonal antibodies including nivolumab and pembrolizumab; anti-PD-L1 antibodies including atezolizumab, avelumab, and durvalumab...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29374302/-durvalumab-improves-prognosis-of-stage%C3%A2-iii-non-small-cell-lung-cancer-after-definitive-chemoradiotherapy
#17
Markus Hecht, Udo S Gaipl, Rainer Fietkau
No abstract text is available yet for this article.
January 26, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29370105/tackling-cancer-resistance-by-immunotherapy-updated-clinical-impact-and-safety-of-pd-1-pd-l1-inhibitors
#18
REVIEW
Shifaa M Abdin, Dana M Zaher, El-Shaimaa A Arafa, Hany A Omar
Cancer therapy has been constantly evolving with the hope of finding the most effective agents with the least toxic effects to eradicate tumors. Cancer immunotherapy is currently among the most promising options, fulfilling this hope in a wide range of tumors. Immunotherapy aims to activate immunity to fight cancer in a very specific and targeted manner; however, some abnormal immune reactions known as immune-related adverse events (IRAEs) might occur. Therefore, many researchers are aiming to define the most proper protocols for managing these complications without interfering with the anticancer effect...
January 25, 2018: Cancers
https://www.readbyqxmd.com/read/29358503/beyond-concurrent-chemoradiation-the-emerging-role-of-pd-1-pd-l1-inhibitors-in-stage-iii-lung-cancer
#19
Neal S McCall, Adam P Dicker, Bo Lu
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC). Although cCRT is potentially curative, 5-year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy. PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC...
March 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29357560/re-safety-and-efficacy-of-durvalumab-medi4736-an-anti-programmed-cell-death-ligand-1-immune-checkpoint-inhibitor-in-patients-with-advanced-urothelial-bladder-cancer
#20
keyword
keyword
56677
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"